Abstract
The present study examined the effect of fenoldopam, a known dopamine-1 receptor (DA1) agonist in order to understand its involvement in the cardiac hypertrophic process. Male Sprague-Dawley rats underwent abdominal aortic constriction (AB) with placement of a suprarenal ligature while sham operated animals served as controls. The AB groupsshowed an increase in their heart wt, left ventricular (LV) wt, heart wt/body wt and LV wt/body wt ratio. Furthermore, the length of these hearts, as measured from the auriculoventricular border to the apex, LV wall and interventricular (IV) septal thickness were increased from control levels. Treatment with SCH 23390, a DA1 antagonist, on the other hand, was able to partially regress the cardiac hypertrophic changes. All these parameters were also increased in control animals treated with fenoldopam (F). Such changes were more striking in the F+AB group which showed a significant acceleration of the cardiac hypertrophic process on super-imposing the two treatments. Plasma dopamine and renin activity were increased in all the groups as compared to control. These results indicate that dopamine receptors are implicated in the development of cardiac hypertrophy.
Similar content being viewed by others
References
Ganguly PK, Mukherjee K, Chen Y: Altered renal dopamine receptors during development of cardiac hypertrophy. Am J Physiol 262: E569-E573, 1992
Antonpillai I, Broers MI, Lang D: Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension 13: 463–468, 1989
Baker KM, Chernin MI, Wixson SK, Aceto JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259: H324-H332, 1990
Ganguly PK, Sherwood GR: Noradrenaline turnover and metabolism in myocardium following aortic constriction in rats. Cardiovasc Res 25: 579–585, 1991
Ganguly PK, Lee S-L, Beamish RE, et al: Altered sympathetic system and adrenoceptors during the development of cardiac hypertrophy. Am Heart J 118: 520–525, 1989
Dodge HT, Sandler H, Ballew DW, Lord JD: The use of biplane angiocardiography for the measurement of left ventricular volume in man. Am Heart J 60: 762–776, 1960
Ganguly PK, Dhalla KS, Innes IR, et al: Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res 59: 684–693, 1986
Ganguly PK, Anderson WA: Involvement of the sympathetic nervous system in the development of cardiac hypertrophy: a fresh look at an old problem. J Auton Pharmac 9: 367–378, 1989
Bertorello A, Aperia A: Inhibition of proximal tubule Na+−K+ATPase activity requires simultaneous activation of DA1 and DA2 receptors. Am J Physiol 259: F924-F928, 1990
Felder RA, Felder CC, Eisner GM, Jose PA: The dopamine receptor in adult and maturing kidney. Am J Physiol 257: F315-F327, 1989
Queseda T, Garcia-Torres L, Alba F, et al: The effects of dopamine on renin release in the isolated perfused rat kidney. Experentia 35: 1205, 1979
Mukherjee K, Sahai A, Ganguly PK: Renal DA1 receptors and not DAI, are upregulated after aortic constriction and may be involved in cardiac hypertrophy. J Auton Pharmacol 14: 307–316, 1994
Kotake C, Hoffman PC, Goldberg LI, Cannon JG: Comparison of the effects of dopamine and beta-adrenergic agonists on adeylate cyclase of renal gomeruli and striatum. Mol Pharmacol 20: 429–434, 1984
Felder CC, Blecher M, Jose PA: Dopamine-1-mediated stimulation of phospholipase C activity in rat renal cortial membranes. J Biol Chem 269: 8739–8745, 1989
Schwartz A: Calcium antagonists: review and perspective on mechanism of action. Am J Cardiol 64: 31–91, 1989
Aceto JF, Baker KM: [Sar1] angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 258: H806-H813, 1990
Francis GS, Wilson BC, Rector TS: Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure. Am Heart J 116: 473–479, 1988
White WB, Radford MJ, Gonzalez FM, et al: Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol 11: 1118–1123, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ganguly, P.K., Mukherjee, K. & Sahai, A. Renal dopamine receptors are involved in the development of cardiac hypertrophy. Mol Cell Biochem 144, 81–84 (1995). https://doi.org/10.1007/BF00926744
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00926744